Alzheimer’s foundation award roundup
Funding for Wave’s stereopure ASO, Optina’s awAIr cerebral amyloid status test
The Alzheimer’s Drug Discovery Foundation announced two awards this week in keeping with its aim to fund a diverse set of therapeutic and biomarker approaches to neurodegeneration, with one a targeted therapy against a disease-driving mutation and the other a biomarker based on retinal scanning.
On Wednesday, ADDF and The Association for Frontotemporal Degeneration (AFTD) disclosed they are teaming up to support the Phase 1b/2a FOCUS-C9 trial of antisense therapy WVE-004 from Wave Life Sciences Ltd. (NASDAQ:WVE). WVE-004 is a stereopure ASO that selectively targets the mutant form of C9orf72, and FOCUS-C9 is a basket trial that will enroll patients with C9orf72 mutations who have been diagnosed with frontotemporal degeneration (FTD), amyotrophic lateral sclerosis (ALS), or FTD with ALS...